InMed Pharmaceuticals (FRA:MWG0) Debt-to-Equity : 0.10 (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals Debt-to-Equity?

InMed Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.32 Mil. InMed Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.67 Mil. InMed Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €10.22 Mil. InMed Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for InMed Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

FRA:MWG0' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.05 Max: 0.24
Current: 0.1

During the past 13 years, the highest Debt-to-Equity Ratio of InMed Pharmaceuticals was 0.24. The lowest was 0.02. And the median was 0.05.

FRA:MWG0's Debt-to-Equity is ranked better than
58.96% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:MWG0: 0.10

InMed Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for InMed Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Debt-to-Equity Chart

InMed Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.05

0.04

0.09

0.03

InMed Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.03	0.03	0.09	0.10

Competitive Comparison of InMed Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, InMed Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InMed Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Debt-to-Equity falls into.

InMed Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

InMed Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.347	+	0.015)	/	11.159
	=	0.03

InMed Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.318	+	0.667)	/	10.217
	=	0.10

InMed Pharmaceuticals (FRA:MWG0) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

InMed Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals (FRA:MWG0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (FRA:MWG0) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

INM:USA MWG0:Germany

Address

815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4

Website

https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (FRA:MWG0) Headlines

No Headlines